Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter

M. Rafiq Islam,1,2 Sanjeev Puri,1,3 Marianna Rodova,1 Brenda S. Magenheimer,1 Robin L. Maser,1 and James P. Calvet1

1Department of Biochemistry and Molecular Biology, and the Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; 2Department of Chemistry/Physics, Northwest Missouri State University, Maryville, Missouri; and 3Department of Biochemistry, Panjab University, Chandigarh, India

Submitted 9 June 2008; accepted in final form 9 October 2008

Islam MR, Puri S, Rodova M, Magenheimer BS, Maser RL, Calvet JP. Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter. Am J Physiol Renal Physiol 295: F1845–F1854, 2008. First published October 15, 2008; doi:10.1152/ajprenal.90355.2008.—The retinoic acids all-trans retinoic acid (AT-RA) and 9-cis retinoic acid (9C-RA) and the retinoic acid receptors RAR and RXR significantly induce transcriptional activity from a 200-bp PKD1 proximal promoter in transfected mammalian cells. This PKD1 promoter region contains Ets, p53, and GC box motifs, but lacks a canonical RAR/RXR motif. Mutagenesis of the Ets sites did not affect RA induction. In contrast, GC box mutations completely blocked stimulation by AT-RA and by RXRβ or RARβ. Mithramycin A, which prevents Sp1 binding, significantly reduced basal promoter activity and suppressed upregulation by AT-RA and RXR. The 200-bp proximal promoter could not be induced by AT-RA in Drosophila SL2 cells, which lack Sp1, but could be activated in these cells transfected with exogenous Sp1. Small interfering RNA knockdown of Sp1 in mammalian cells completely blocked RXRβ upregulation of the promoter. These data indicate that induction of the PKD1 promoter by retinoic acid is mediated through Sp1 elements. RT-PCR showed that AT-RA treatment of HEK293T cells increased the levels of endogenous PKD1 RNA, and chromatin immunoprecipitation showed the presence of both RXR and Sp1 at the PKD1 proximal promoter. These results suggest that retinoids and their receptors may play a role in PKD1 gene regulation.

all-trans retinoic acid; 9-cis retinoic acid; RAR; RXR

AUTOSOMAL DOMINANT POLYCYSTIC kidney disease (ADPKD) is a human genetic disorder with a frequency of 1 in 200–1,000 individuals and accounts for ~10% of end-stage renal disease (2, 6, 22, 29, 47, 53, 58, 65). Approximately 85% of all ADPKD cases are due to mutations in the PKD1 gene, whose gene product is a large, membrane-spanning protein, polycystin-1. The remaining cases are due to mutations in the PKD2 gene. All ADPKD patients develop bilateral cystic kidneys. They can also have a variety of other extrarenal manifestations, including liver cysts, coronary artery disease, cardiac hypertrophy, hypertension, and cerebral aneurysms (17, 18, 20, 26, 48, 61).

While a two-hit loss-of-function mechanism has been hypothesized as the genetic cause of cyst initiation (5, 51, 52), there are conflicting observations as to whether cysts always result from abnormally decreased expression of the PKD genes and whether loss of both alleles is always required. On the one hand, Pkd1(−/−) mice usually die in utero with massively cystic kidneys and cardiovascular abnormalities (4, 32, 38, 39, 44). On the other hand, there is evidence that haploinsufficiency at the Pkd1 locus can cause disease (36); there is immunocytochemical evidence for overexpression of polycystin-1 in cystic kidneys (46), and transgenic mice overexpressing a functional human PKD1 gene develop renal cysts (49, 60). Thus it is possible that ADPKD may be caused either by abnormally decreased (1- or 2-hits) or abnormally increased expression of the PKD1 gene.

Polycystin-1 appears to be developmentally regulated, with high expression during early embryogenesis in many tissues and organs, which decreases postnataally and is maintained at low levels in adults (9). Furthermore, the levels of PKD1 gene expression and polycystin-1 protein appear to govern in vitro cystogenesis (45). Thus any abnormality in the tight regulation of polycystin-1 protein levels may have important implications for normal physiological function and for cyst formation. Taken together, these observations signify the need to understand the transcriptional mechanisms regulating polycystin-1 levels. Earlier, our laboratory showed that the human PKD1 gene can be upregulated by β-catenin via a TCF/LEF consensus motif present within the PKD1 promoter (54). A number of other studies have also implicated β-catenin in the pathogenesis of PKD (28, 31, 62). We have also shown that the PKD1 proximal promoter contains two Ets binding elements, which are able to respond to the Ets factors Ets-1 and Fli-1 (50). It has also been recently demonstrated that p53 is a transcriptional repressor of PKD1, acting at the proximal promoter region (63). To further understand the mechanisms regulating PKD1 transcription, we have now looked for additional elements that could potentially regulate the expression of the PKD1 gene.

The retinoids, including all-trans retinoic acid (AT-RA) and 9-cis retinoic acid (9C-RA), are biologically active derivatives of vitamin A (13, 41). They have profound effects on the regulation of cell growth, differentiation, and apoptosis during embryonic development and within epithelial tissues in later life (8, 40, 42). The retinoids exert their effects through isoforms of RAR and RXR, the retinoic acid receptors, which are members of the nuclear hormone receptor superfamily. The RAR/RXR isoforms are ligand-dependent transcription factors that bind to DNA sequences, called RAR-elements (RAREs) or RXR-elements (RXREs), present in the promoter regions of target genes, including the RAR and RXR genes themselves.

http://www.ajprenal.org 0363-6127/08 $8.00 Copyright © 2008 the American Physiological Society F1845

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Upon ligand binding, the RARs/RXRs upregulate transcription of target genes through a variety of coactivators, such as steroid receptor coactivator-1 and p300/CPB [cAMP-response element binding protein (CREB)-binding protein] (10, 21, 24, 27, 66). In genes without canonical RA response elements, the RARs/RXRs have been shown to bind to and modulate activity of the transcription factor Sp1, resulting in an Sp1-mediated response to RA signaling (56, 59). Sp1 binds to a hexanucleotide sequence GGGCGG, called the “GC box” motif, or to variations of this sequence in which one or two nucleotides are substituted. Sp1 then activates transcription of GC box-containing genes by recruiting RNA polymerase II (19, 35). Disruption of one RXR isofrom, RXRα, has been shown to cause conotruncal defects in mice, which are almost identical to the cardiac phenotype of Pkd1 null mice, suggesting that retinoids and Pkd1 may interact to play an important role in normal cardiac development (44).

In the present study, we have found that AT-RA, 9C-RA, and the RA receptors RAR and RXR activate the Pkd1 promoter through a 200-bp proximal promoter region. We determined that there is an absence of canonical RAR or RXR elements in the 200-bp Pkd1 proximal promoter, but that promoter activity is mediated through the ubiquitous transcription factor Sp1 and its binding sites in the proximal Pkd1 promoter.

**MATERIALS AND METHODS**

**Plasmid constructs.** A 3.3-kb human Pkd1 promoter fragment (−3,346 to +33) subcloned in the promoterless luciferase reporter vector pGL2-Basic (Promega) was originally generated in our laboratory (54). Promoter deletion constructs (1.3 kb, 2.0 kb, and 200 bp) cloned in pGL2-Basic and/or pGL3-Basic were described previously (50, 54). The mammalian expression construct for Sp1 was from Dr. Ronald M. Evans (Howard Hughes Medical Institute, the Salk Institute). The Sp1 pPac constructs for RAR and RXR were from Dr. Yu-Chung Yang (Dept. of Pharmacology and Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH). The constructs for RAR and RXR were from Dr. Ronald M. Evans (Howard Hughes Medical Institute, the Salk Institute). The Sp1 pPac clone, for expression in Drosophila SL2 cells, was from Dr. Yu-Chung Yang.

**Mutagenesis.** Two potential Ets binding sites (Ets-A and Ets-B) (50) and four of the six Sp1 sites (Sp1-A through Sp1-F) in the 200-bp proximal promoter region were mutated using the QuikChange site-directed mutagenesis kit (Stratagene) and the following double-stranded primers: Ets-A, 5'-GTG GGG CGG AGC Tct CGG AGG-3'; Ets-B, 5'-GGA GGG TGA AGC CTC gtG ATG CGC CGC TCT CAT CG-3'; Sp1-A, 5'-CCG GTG Gtt CGG AGC TTC CGG-3'; Sp1-B, 5'-GAG GCC aaG CCC TGC TGC CG-3'; Sp1-C, 5'-G CGA AGG Gtt CGG AGC CTG-3'; and Sp1-F, 5'-CC GTC taC CCC GCC CGG CCGC-3'. The lowercase nucleotides represent the mutations. The 200-bp mutant fragments were subcloned into pGL2 and/or pGL3 and verified by sequencing.

**Cells, transfections, and reporter assays.** HEK293T cells were grown overnight in six-well plates (1.7 ml/well) without serum and antibiotics (solution 1). Lipofectamine 2000 (Invitrogen) method according to the manufacturer’s instructions. Vector DNA or RXRβ expression plasmid (0.4 μg DNA) and the Pkd1 promoter-luciferase reporter with or without siRNA duplex (80 pmol) against human Sp1 (SC-29487, Santa Cruz Biotechnology) were mixed with DMEM (total volume 150 μl/well) without serum and antibiotics (solution 1). Lipofectamine 2000 (6 μg/well) was diluted in DMEM (150 μl/well) without serum and antibiotics (solution 2). Solutions 1 and 2 were mixed and incubated for 25 min at room temperature. The solution was added to the cells and the samples were incubated overnight at 37°C. Following incubation, the medium was replaced with fresh DMEM containing 5% serum and antibiotics, and the cells were harvested at 40 h.

**SDS-PAGE and western blotting.** Expression of Sp1 in AT-RA-treated HEK293T cells was confirmed by 10% SDS-PAGE, followed by immunoblotting using rabbit anti-Sp1 antibody (sc-59, 1:10,000, Santa Cruz Biotechnology) and alkaline phosphate-conjugated secondary antibody (1: 8,000, Sigma). The protein bands were detected using CDP-Star (Amersham). The blots were reprobed with rabbit anti-actin antibody (A7434, Sigma).

**Chromatin immunoprecipitation.** HEK293T cells were cross-linked for 10 min in 1% formaldehyde in PBS at room temperature. Cross-linking was stopped by adding glycine to a final concentration of 125 mM. Cells were washed with ice-cold PBS, harvested by centrifugation for 2 min at 5,000 rpm, resuspended in 0.5 ml of chromatin immunoprecipitation (ChIP) lysis buffer (10 mM Tris·HCl, pH 8.0, containing 10 mM NaCl, 0.5% NP-40, 1 mM EDTA, and protease inhibitor cocktail), and incubated on ice for 15 min. The crude nuclear extract collected by centrifugation at 2,500 rpm for 5 min was washed once with 0.2 ml of PBS, resuspended in 500 μl of 1× IP buffer (0.5% Triton X-100, 0.5% NP-40, 0.1% SDS in PBS, and protease inhibitor cocktail), and fragmented by sonication: 4 pulses for 15 s with 30-s cooling periods on ice, using a 2-mm probe at 60% output (Sonics model VCE 130, maximum 130 W). The fragmented chromatin was incubated with 5 μl of rabbit preimmune sera (R9133, Sigma), rabbit anti-RXR (D-20, Santa Cruz Biotechnology), or rabbit anti-Sp1 (PEP2, Santa Cruz Biotechnology). Following washing 3× with wash buffer (50 mM Tris·HCl, pH 8.0, containing 0.15 M NaCl, 0.5% Triton X-100, 0.5% NP-40, 0.1% SDS, 1 mM EDTA), the cross-links were reversed with elution buffer (1% SDS, 0.1 M NaHCO3, 0.4 M NaCl) for 3 h at 67°C. The DNA in the supernatant was purified by using a High Pure PCR Product Purifi-
cation Kit (Boehringer Mannheim) and amplified for 35 cycles of 94°C for 45 s, 62°C for 45 s, 72°C for 45 s, with a final extension of 7 min at 72°C using the forward primer 5'-CTG CTG CGC ACC CTG TGG AG-3' and the reverse primer 5'-CGC GCG GCG GGC GGA CGG-3' (135-bp product). The products were confirmed by sequencing.

Endogenous PKD1 expression. HEK293T cells were treated with ethanol or AT-RA in DMEM containing 2% serum for 40 h. Total RNA was extracted with TRIzol (Invitrogen) according to the manufacturer's protocol, and the samples were treated with DNase I (Ambion). RT-PCR was carried out with 1 μg RNA in a total volume of 25 μl using random primers and Superscript reverse transcriptase (Invitrogen) as described previously (54). Primers specific for PKD1 were forward, 5'-CGC CGC TTC ACT AGC TTC GAC-3', giving a 260-bp product; primers specific for the ribosomal protein L7 were forward, 5'-GCT TCG AAA GGC AAG GAG GAA GC-3', and reverse, 5'-GCG GCG GCG CGG GGC GGA CGG-3', giving a 440-bp product. Amplified PCR fragments were electrophoresed on 2% agarose gels containing ethidium bromide, and the bands were analyzed by National Institutes of Health Image software. Quantified band intensity was normalized to values for ribosomal protein L7 mRNA and plotted as relative units. The data were plotted with Microsoft Excel as the average ± SD of three independent experiments.

RESULTS

The PKD1 promoter is activated by retinoic acids and their receptors. The 3.3-kb PKD1 promoter and its two proximal fragments, 2.0 kb and 200 bp, were found to have high basal promoter activity in transfected HEK293T cells and to be significantly induced by AT-RA treatment (Fig. 1, A and B). In contrast, the distal 1.3-kb fragment was found to have lower basal activity and to be less responsive to AT-RA. Our previous studies showed that the 200-bp proximal fragment has high promoter activity, suggesting that it contains functionally important transcriptional elements (54). Indeed, it has been recently shown that the 200-bp proximal fragment has functionally responsive Ets and p53 sites (50, 63). The relatively strong response to AT-RA of the 200-bp proximal promoter fragment suggests that the primary retinoic acid response is mediated by elements within the first 200 bp. Deletion analysis (data not shown) of the 2.0 kb promoter confirmed that the 200-bp proximal fragment is responsible for AT-RA induction. This AT-RA induction varied from 3-fold to up to >10-fold, depending on the experiment.

The 200-bp PKD1 promoter fragment responded to both 9C-RA and AT-RA in a dose-dependent fashion (Fig. 2). This PKD1 promoter fragment also responded to AT-RA in monkey kidney COS-1 cells and human colon carcinoma HCT116 cells (Fig. 3), indicating that the response is not specific to HEK293T cells. It was also possible to stimulate the 200-bp promoter-reporter ~2.5–6-fold by transfection of retinoic acid receptors alone, with RARβ showing the highest activity (Fig. 4). The only exception was RARγ, which elicited no increase over basal promoter activity. These data suggest that sequences in the 200-bp PKD1 proximal promoter can respond to vitamin A metabolites and their nuclear receptors.

The 200-bp PKD1 proximal promoter lacks a canonical RAR/RXR response element. Sequence analysis revealed that the 200-bp proximal promoter region does not have an RAR/RXR response element (Fig. 5). We recently showed that this proximal promoter sequence does have two consensus Ets elements (EREs), Ets-A and Ets-B, and there are two consensus p53 elements (Fig. 5) (50, 63). As there are reports that Ets factors can mediate a retinoic acid response and can modulate transcription of RA target genes (30), we thought that the EREs might be involved in RA-mediated transcriptional upregulation of the PKD1 promoter. To test this idea, site-directed mutagenesis was used to selectively disrupt the core EREs at each Ets site. Mutations were introduced either at Ets-A or Ets-B, and at both Ets-A and Ets-B (Fig. 5). The effects of these mutations were then determined in HEK293T cells following RA treatment. None of these ERE mutants, however, was able to suppress the transcriptional stimulation by AT-RA (data not shown).

Sp1 elements mediate the RA response. The 200-bp sequence was also found to contain six canonical “GC box” (GGGCGG) motifs (Sp1-A to Sp1-F). Sp1 binds the canonical GC box motif with high affinity. The PKD1 promoter lacks TATA and CAAT boxes, and thus its basal transcription, like numerous other TATA-less promoters, may depend on Sp1. In genes without canonical RA response elements, the RARs/
RXRs, have been shown to modulate the activity of Sp1, resulting in an Sp1-mediated response to RA signaling (56, 59). Thus we thought that RA might activate the PKD1 promoter through one or more of these Sp1 sites. Mutations were introduced into Sp1-A, Sp1-B, Sp1-C, and Sp1-F (Fig. 5). A double mutant at Sp1-B and Sp1-C (Sp1-BC) and a triple mutant at Sp1-B, Sp1-C, and Sp1-F (Sp1-BCF) were also generated. As shown in Fig. 6, mutations at either Sp1-A or Sp1-B alone did not cause a decrease in basal or RA-induced promoter activity. While the Sp1-C single mutation seemed to have little or no effect on basal or induced promoter activity, the Sp1-BC double mutation had significantly decreased basal

activity and a reduced AT-RA responsiveness compared with wild-type (Fig. 6, bottom). The Sp1-F single mutation also had significantly decreased basal activity and a reduced AT-RA responsiveness. All of the single or double mutants could also be induced by cotransfected RXRβ (data not shown). In contrast to the above results, the triple mutant (Sp1-BCF), showed an almost complete loss of both basal promoter activity and induced promoter activity in response to either AT-RA or 9C-RA (Fig. 7A) or to the nuclear receptors RXRβ or RARβ (Fig. 7B). This result suggested that the RA response is mediated primarily through a combination of Sp1 sites that includes but is not restricted to Sp1-F. As mutations at site Sp1-B alone had no effect on basal and AT-RA- or RARβ-stimulated activities (Fig. 6 and data not shown), and mutations at sites Sp1-C or Sp1-F alone caused some reductions in
Exogenous Sp1 activates the 200-bp PKD1 promoter. As Drosophila SL2 cells lack Sp1, but contain RAR/RXR homologs, we exploited this unique property of these cells to test the response of the 200-bp PKD1 promoter to exogenous Sp1. As shown in Fig. 10, the activity of the 200-bp promoter was significantly increased in the absence or presence of AT-RA after the cells were supplied with exogenous Sp1. In contrast, the promoter was not induced at all by AT-RA in the absence of Sp1. Taken together, these data support the idea that Sp1 can activate this promoter and thus can mediate the retinoid response.

To determine in mammalian cells whether exogenous Sp1 in combination with exogenous RXRβ or AT-RA treatment can stimulate the 200-bp PKD1 promoter, we cotransfected Sp1-transfected HEK293T cells with RXRβ, or treated Sp1-transfected cells with AT-RA. As shown in Fig. 11A, additional Sp1 led to activation of the 200-bp promoter, and this induction by exogenous Sp1 was further augmented by RXRβ, and even more so by AT-RA. As shown in the Western blot (Fig. 11B, left), HEK293T cells contain endogenous Sp1, which was not increased in AT-RA-treated cells or in RXRβ-transfected cells, thus indicating that the responses of the PKD1 promoter to AT-RA induction, it is likely that a combination of Sp1-C and Sp1-F mediate the RA response in concert. Repeated attempts to introduce mutations into Sp1-D/Sp1-E failed, making it impossible to test these sites; however, the fact that the triple mutant Sp1-BCF was almost completely inactive makes it impossible to test these sites; however, the fact that the triple mutant Sp1-BCF was almost completely inactive makes it unlikely that Sp1-D/Sp1-E has a role in RA responsiveness.

MthA completely blocks RA and RXR responses. To test whether any of the GC boxes present in the 200-bp promoter sequence are induced by endogenous Sp1, we treated promoter-transfected HEK293T cells with MthA, a GC box inhibitor that sequence are induced by endogenous Sp1, we treated promoter-

Fig. 6. Effect of GC box mutations on the response to AT-RA. Single and double mutations of GC box motifs in the 200-bp PKD1 promoter fragment were generated by substituting 2 base pairs within each core consensus site as shown in Fig. 5. HEK293T cells were transfected with 1.0 μg of wild-type (WT) 200-bp promoter-luciferase reporter or the mutant constructs (Sp1-A, Sp1-B, Sp1-C, Sp1-BC, or Sp1-F) in pGL3. The transfected cells were incubated with either ethanol (−) or 5 μM AT-RA (+) for 6 h. Luciferase values were normalized to β-galactosidase activities. The average RLU value obtained for the ethanol (−)-treated, WT-transfected cells was set at 1.0. Each bar is the mean ± SD of a representative experiment done in triplicate. Top: Sp1-A, Sp1-B, and Sp1-C mutations were all inducible (*P < 0.05, **P < 0.01) but had little effect on basal activity. Bottom: Sp1-BC and Sp1-F mutations were inducible (*P < 0.05) and had decreased basal and induced activities (#P < 0.05, ##P < 0.01) compared with the WT basal and induced control activities.

AT-RA induction, it is likely that a combination of Sp1-C and Sp1-F mediate the RA response in concert. Repeated attempts to introduce mutations into Sp1-D/Sp1-E failed, making it impossible to test these sites; however, the fact that the triple mutant Sp1-BCF was almost completely inactive makes it unlikely that Sp1-D/Sp1-E has a role in RA responsiveness.

MthA completely blocks RA and RXR responses. To test whether any of the GC boxes present in the 200-bp promoter sequence are induced by endogenous Sp1, we treated promoter-transfected HEK293T cells with MthA, a GC box inhibitor that specifically blocks interaction between Sp1 and the GC motif by masking GC-rich sequences (7, 23). As shown in Fig. 8, MthA treatment reduced the basal activity of the 200-bp PKD1 promoter by 70%, suggesting that one or more of the GC boxes is functional and that Sp1 is involved in basal transcription. As expected, MthA treatment had virtually no effect on the already very low basal activity of the Sp1-BCF mutant.

To further establish a link between RA-mediated activation and Sp1, cells transfected with the wild-type 200-bp PKD1 promoter were treated with AT-RA in the absence or presence of MthA. As shown in Fig. 9 (left), the 10-fold activation of the promoter by AT-RA was completely suppressed by MthA. Induction of promoter activity by cotransfected RXRβ was also fully abolished by MthA (Fig. 9, right). These data further support the idea that Sp1 mediates the stimulation of the 200-bp PKD1 promoter by retinoid treatment.

Fig. 7. Sp1-BCF mutant is not inducible by retinoic acids or their receptors. The triple mutant, Sp1-BCF, was created by introducing mutations at the Sp1-B, Sp1-C, and Sp1-F sites in the 200-bp fragment. A: HEK293T cells were transfected with 1.0 μg of WT 200-bp promoter-luciferase reporter or the triplet mutant construct in pGL3. The transfected cells were incubated with either ethanol (−), 5 μM AT-RA, or 10 μM 9C-RA for 6 h. Luciferase values were normalized to β-galactosidase activities. B: HEK293T cells were transfected with 0.2 μg of WT 200-bp promoter-luciferase reporter or the triplet mutant construct in pGL3 together with 0.2 μg pcDNA3 (−), RXRβ, or RARβ. After transfection, the cells were incubated in growth medium containing 2% serum for 40 h. Luciferase values were normalized to protein concentration. The average RLU value obtained for the control (−) WT-transfected cells was set at 1.0. Each bar is the mean ± SD of a representative experiment done in triplicate. The Sp1-BCF mutation significantly decreased basal (###P < 0.01) and induced (####P < 0.001) activities compared with the WT basal and induced control activities.
RXRβ and AT-RA did not involve upregulation of endogenous Sp1. In contrast, Sp1 was significantly increased in the Sp1-transfected cells (Fig. 11B, right), thus explaining the augmentation of promoter activity in Sp1-transfected cells.

To further demonstrate the involvement of Sp1 in promoter activation by the RA receptor, siRNA knockdown experiments were carried out. As shown in Fig. 12, activation of the 200-bp PKD1 promoter by RXRβ was completely abolished by Sp1-specific siRNA knockdown. Western blot analysis of cells in parallel experiments showed a significant reduction of Sp1 compared with a β-actin control.

The PKD1 gene is upregulated by AT-RA and binds RXR. To determine whether expression of the endogenous PKD1 gene responds to RA, total RNA was isolated from AT-RA-treated HEK293T cells and analyzed by RT-PCR. As shown in Fig. 13 (A–C), PKD1 mRNA levels were increased ~1.6-fold, whereas the ribosomal protein L7 mRNA was not affected by the treatment. As shown in Fig. 13D, there was a dose-response to AT-RA which increased PKD1 mRNA levels up to 2.6-fold at the maximum dose of 5 μM AT-RA.

To determine whether RXR binds the proximal promoter in vivo, ChIP-PCR assays were carried out with an anti-RXR antibody. As shown in Fig. 14 (lane 3), a PCR product similar in size to that obtained with the input DNA was seen, indicating that RXR is bound to a region within the PKD1 proximal promoter. This 135-bp promoter region includes Sp1-C and Sp1-F (the locations of the forward and reverse primers are shown in Fig. 5). Because this promoter region does not contain an RAR/RXR element, it is likely that RXR is bound indirectly through Sp1. As shown in lane 4, Sp1 was also found present on this 135-bp promoter region (Fig. 14). These results suggest that the PKD1 gene is a target of retinoid activation mediated through Sp1.

DISCUSSION

In the present study, we report that the human PKD1 promoter is a target for vitamin A metabolites. This response was localized to the proximal 200-bp region upstream of the transcription start site. A 200-bp PKD1 promoter-reporter construct was typically induced up to >10-fold by RA (AT-RA or 9C-RA) treatment in transient transfection assays using three different cell lines. Activation of the 200-bp promoter-reporter was also observed in response to cotransfected RARα, RARβ, and RXRβ (but not RARγ). These results suggested that activation of the proximal region of the PKD1 promoter involves activation of RA receptors and that the PKD1 gene may be a target of RAR/RXR. Sequence analysis of the 200-bp PKD1 proximal promoter region identified two Ets elements, two p53 elements (63), and six GC boxes (Sp1-A thru Sp1-F), but no canonical RARE. However, not all effects of RAs are directly regulated by interactions between RAR/RXR and
RAREs, and a number of mechanisms through which the retinoids stimulate gene transcription have been reported. These include inactivation of AP-1 via a CREB-binding protein-regulated pathway (66), inhibition of JNK (66), modulation of histone acetylation (27), and Ets- or Sp1-mediated activation (30, 56, 59).

ChIP showed that both Sp1 and RXR were bound to the PKD1 promoter in a 135-bp region that lies within 170 bp of the transcription start site, suggesting that RXR interacts with DNA-bound Sp1 at the proximal PKD1 promoter. Mutation of three of the GC boxes in the Sp1-BCF triple mutant eliminated all basal promoter activity and completely abolished the response to both retinoids (AT-RA and 9C-RA) and to both RXRβ and RARβ. Since the Sp1-B mutation alone had no effect on basal or induced activity, whereas the individual Sp1-C and Sp1-F mutations decreased promoter activity and the Sp1-BCF triple mutation had no promoter activity, it is likely that both Sp1-C and Sp1-F are functional Sp1 sites that are responsive to retinoid activation.

Similar observations were described for the urokinase plasminogen activator promoter (56). This promoter contains three canonical GC boxes and one atypical GC box within a 42-bp proximal promoter sequence. Mutation of the distal-most (canonical) site had no effect on either basal or hormone-induced activity, whereas a combination of mutations in the other three sites caused elimination of most basal and receptor-stimulated activity. Thus not all canonical GC box motifs are necessarily functional. Furthermore, a number of studies (11, 33, 34, 56) have identified the importance of 3′-flanking sequences immediately adjacent to the hexanucleotide core GC box motif in determining functionality. The presence of five or more purines or pyrimidines in the 3′-flanking region may reduce or completely abolish function, as observed in transforming growth factor (TGF)-β1 (CTCCCC and CCCCC), TGF-β RII (AGGGGG), TGF-β RII (AGAGAGG), and MDR1 (GGAGCA), as they may interfere with binding of Sp1 to the GC box (56). In contrast, a mixture of purines and pyrimidines in the 3′-flanking region may support Sp1 binding. In the PKD1 promoter, the 3′-flanking regions of Sp1-A (AGCTTCC) and Sp1-B (GGCCTTCC) contain five continuous pyrimidines, while those of Sp1-C (AGCCCTGC) and Sp1-F (ACGGGGGA) have mixed purine and pyrimidine sequences consistent with functional GC box motifs. We did not directly test the combined Sp1-D/Sp1-E sequence. However, the fact that the Sp1-BCF triple mutant completely abrogated promoter activity argues that the Sp1/D Sp1-E sequence is not functional in either basal regulation or in the RA response.

MthA blocks interactions between Sp1 and GC boxes by obscuring GC-rich sequences (7, 23). MthA treatment significantly reduced (∼70%) basal activity of the wild-type PKD1 promoter, suggesting that it does so by preventing the binding of Sp1 to functional GC box motifs, most likely Sp1-C and Sp1-F. However, the incomplete inhibition of basal activity suggests that MthA was not completely effective at these sites, since both basal and induced promoter activities were almost completely abolished in the Sp1-BCF triple mutant. MthA completely inhibited both AT-RA and RXRβ-induced pro-

---

**Fig. 11.** Effect of exogenous Sp1 on basal and induced PKD1 promoter activity in HEK293T cells. A: cells were transfected with 0.5 μg of WT 200-bp PKD1 promoter construct, together with 0.4 μg of pCDNA3 alone (−), 0.2 μg pCDNA3+0.2 μg of Sp1, or 0.2 μg Sp1+0.2 μg RXRβ. Fifty nanograms of a β-galactosidase construct was included in each transfection. The transfected cells were incubated with growth medium containing 2% serum only or were supplemented with ethanol (−) or 1 μM AT-RA for 40 h. Luciferase values were normalized to β-galactosidase or to protein concentration. The average RLU value obtained for the untreated cells (far left) was set at 1.0. Each bar is the mean ± SD of a representative experiment done in triplicate. The 200-bp construct was induced by exogenous Sp1 (*P < 0.05) and further induced by the combination of Sp1 and RXRβ (**P < 0.01) or Sp1 and AT-RA (***P < 0.001). B: Western blot showing expression of Sp1 in untransfected cells (Cels), cells transfected with vector alone (pCDNA3), untransfected cells treated with AT-RA (AT-RA), and cells transfected with RXRβ (RXRβ). Also shown are cells transfected with vector (pCDNA3) compared with cells transfected with Sp1 (Sp1). Equal amounts of protein (30 μg) were analyzed and compared with a β-actin loading control.

---

**Fig. 12.** Knockdown of Sp1 blocks RXRβ induction of the PKD1 promoter. HEK293T cells were transfected with the 200-bp promoter-luciferase construct (0.5 μg), β-galactosidase, and pCDNA3 or RXRβ (0.4 μg), with or without Sp1-small interfering RNA (siRNA) duplex (80 pmol). The cells were harvested 40 h posttransfection and assayed for luciferase and β-galactosidase. The average luciferase value obtained for control transfected cells was set at 1.0. Each bar is the mean ± SD of a representative experiment done in triplicate. RXRβ-induced activity (*P < 0.05) was blocked by siRNA knockdown (#P < 0.05). Right: HEK293T cells transfected in parallel experiments with (+) or without (−) Sp1-siRNA were analyzed for the presence of Sp1 and β-actin (as a control) by Western blotting.
showing that neither AT-RA nor RXR blocked RXR levels (Fig. 11B). Furthermore, siRNA knockdown of Sp1 for 40 h in growth medium containing 2% serum, o r changed Sp1 protein levels (Fig. 11B). Furthermore, siRNA knockdown of Sp1 in HEK293T cells blocked RXR\(\beta\) induction of the promoter (Fig. 12). Taken together, these results suggest that RA and its receptors facilitate Sp1 activation of the PKD1 promoter.

Transactivation of the PKD1 promoter by retinoids may occur in a similar manner to that seen for the urokinase transglutaminase, TGF-\(\beta\), and TGF-\(\beta\) RI promoters, by mediation of the interaction between Sp1 and GC box motifs (11, 33, 34, 56). In those studies, it was found that RA and its receptors failed to increase Sp1 mRNA or protein but that a physical interaction between Sp1 and the RARs/RXRs receptor dimer is an intermediate to induction by RA. In this case, RA treatment first induced expression of RA receptors through RARE sites (8, 40, 42). The RARs then physically interacted with Sp1 together with RXR and enhanced Sp1 binding to GC box motifs, resulting in Sp1-mediated upregulation of gene transcription (56). Both types of receptors had the same ability to mediate Sp1 binding, and in vivo they appeared to act synergistically. Similar interactions between Sp1 and the estrogen receptor have also been observed (16, 55, 57, 64). In contrast, it has been shown that RA activation of thrombomodulin gene transcription can occur by induction of both Sp1 mRNA and protein in RA-treated cells (25).

Sp1 family transcription factors play a key role in regulating transcription initiation at TATA-less promoters (3), and they are temporally and spatially regulated during vertebrate morphogenesis and are important for normal organogenesis (67). Similarly, the retinoids have profound effects on many essential biological programs, including cellular growth, somatic cell differentiation, and morphogenesis (42). In situ hybridization and RNA protection analyses have indicated distinct and often mutually exclusive expression patterns of some of the RA receptor isoforms (14, 15). We have demonstrated that expression of the endogenous PKD1 gene was elevated in response to AT-RA treatment in HEK293T cells (Fig. 13), supporting the idea that the endogenous PKD1 gene is a target of vitamin A-derived metabolites. It has been reported that targeted disruption of RXRs causes cardiac conotruncal defects identical to the cardiac phenotype found in Pkd1 null mouse embryos (44), suggesting that the Pkd1 gene may be a critical target of RA signaling in the heart. It has also been shown that a retinoid, N-(4-hydroxyphenyl) retinamide, markedly inhibited cystogenesis of ADPKD cyst-derived cells, Madin-Darby canine kidney cells, and rat epithelial cells in collagen matrix cultures (1). As such, PKD therapies may include treatment with retinoid acid derivatives and could be beneficial in cases of PKD1 haploinsufficiency.

**ACKNOWLEDGMENTS**

We thank Dr. Yu-Chung Yang (Dept. of Pharmacology and Cancer Center, School of Medicine, Case Western Reserve University) for the Sp1 constructs and Dr. Ronald M. Evans (Howard Hughes Medical Institute, the Salk Institute) for the RAR and RXR expression constructs, Kyle Jansson and Yvonne Wan for help with the RA-treatment experiments, and Dr. Mike Wolfe for critically reading the manuscript.

![Fig. 14. RXR and Sp1 bind within the proximal promoter of the PKD1 gene. ChIP-PCR analysis was carried out in untransfected HEK293T cells, as described in MATERIALS AND METHODS. The formaldehyde-cross-linked, sonicated DNA was immunoprecipitated before PCR, and the amplified products were analyzed by gel electrophoresis. Lane 1, cross-linked input DNA (not immunoprecipitated); lane 2, cross-linked, rabbit preimmune serum immunoprecipitated DNA; lane 3, cross-linked, anti-RXR immunoprecipitated DNA (RXR); lane 4, cross-linked, anti-Sp1 immunoprecipitated DNA (Sp1).](http://ajprenal.physiology.org/ Downloaded from http://ajprenal.physiology.org/ by 10.220.33.2 on March 30, 2017)
RETINOIDs UPREGULATE PKD1 THROUGH Sp1

F1853

GRANTS

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants P50-DK-057301 (J. P. Calvet) and R15-DK-069897 (M. R. Islam).

REFERENCES


